We use cookies to help us improve the website and your experience using it. You may delete and block all cookies from this site at any time. However, please note this may result in parts of the site no longer working correctly. If you continue without changing your settings we will assume you are happy to receive all cookies on this site.


Funding for new study in childhood nephrotic syndrome

Dr Nicholas Webb, Consultant Paediatric Nephrologist at the Royal Manchester Children's Hospital and Director of the Wellcome Trust Children's Clinical Research Facility, has been awarded a grant of £734,697 by the NIHR Health Technology Assessment programme.

The funding is to perform a national, multi-centre, randomised controlled study of different prednisolone treatments in childhood nephrotic syndrome. The study, known as the PREDNOS study, will involve 225 children in over 50 centres, who will receive either eight weeks or sixteen weeks of prednisolone therapy.

The purpose of the study is to see whether increasing the duration of therapy reduces the number of children who have disease relapses without significantly increasing side effects. A formal health economic analysis is being performed as part of this study.

Additional studies will be performed in collaboration with the Institute of Child Health London, in an attempt to determine whether there are any underlying genetic abnormalities associated with the disease. The study will be run through the University of Birmingham Clinical Trials Unit in collaboration with the UK Medicines for Children Research Network, who will play a pivotal role in the identification and set up of study centres.